Time of effect duration and administration interval for sitagliptin in patients with kidney failure
Authors:
- 19 December 2013
- journal article
- research article
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 39 (2) , 77-85
Abstract
A measure correlating the time course of the effect with the time course of concentrations could be helpful in drug dosing. We propose a new equation with explicit solutions for calculating the effect duration. A specific effect fraction is selected (fr) and the time of fractional effect duration (TED.fr) can be derived as a function of the elimination half-life by combining linear elimination kinetics with sigmoid effect dynamics. This new measure is applied to the example of sitagliptin, whose elimination half-life increases from 10.1 to 28.4 h in patients with kidney failure. Under normal multiple-dose conditions, the 24-h sitagliptin administration interval corresponds to a 0.90 time of fractional effect duration (TED.90). A dose reduction to one-fourth or 25 mg every 24 h is proposed for patients with kidney failure; this results in a TED.90 of 45 h, i.e. 21 h longer than the proposed 24-h administration interval (+88 %). The proportional dosing alternative of 100 mg every 96 h would result in a TED.90 of 64 h, which is 32 h less than the 96-h administration interval (−33 %). With a half dose of 50 mg and a doubled administration interval of 48 h, the TED.90 is 51 h in kidney failure, only 3 h longer than the latter administration interval (+6 %). We conclude that our general equation can be applied to rapidly calculate the specific time of effect duration for the different dose schedules.Keywords
This publication has 26 references indexed in Scilit:
- On the Accuracy of a One-Compartment Approach for Determination of Drug Terminal Half-LifeJournal of Pharmaceutical Sciences, 2013
- Intermittent drug dosing intervals guided by the operational multiple dosing half lives for predictable plasma accumulation and fluctuationJournal of Pharmacokinetics and Pharmacodynamics, 2011
- Evaluation of pharmacokinetic parameters and dipeptidyl peptidase‐4 inhibition following single doses of sitagliptin in healthy, young Japanese malesBritish Journal of Clinical Pharmacology, 2010
- The Operational Multiple Dosing Half-life: A Key to Defining Drug Accumulation in Patients and to Designing Extended Release Dosage FormsPharmaceutical Research, 2008
- Disposition of the Dipeptidyl Peptidase 4 Inhibitor Sitagliptin in Rats and DogsDrug Metabolism and Disposition, 2007
- Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteersClinical Therapeutics, 2006
- Context-Sensitive Half-TimesClinical Pharmacokinetics, 2002
- Determining the Trough-to-Peak Ratio in Parallel-Group TrialsHypertension, 1997
- The kidney in pre-clinical and clinical pharmacokinetics.Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 1984
- Kinetics of pharmacologic response I. Proposed relationships between response and drug concentration in the intact animal and manJournal of Theoretical Biology, 1968